Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;32(1):e20.
doi: 10.3802/jgo.2021.32.e20. Epub 2020 Dec 2.

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?

Robert L Coleman  1
Affiliations
Comment

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?

Robert L Coleman. J Gynecol Oncol. 2021 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Comment on

  • Why was GOG-0213 a negative trial?
    Ehmann S, Zivanovic O, Chi DS. Ehmann S, et al. J Gynecol Oncol. 2021 Jan;32(1):e19. doi: 10.3802/jgo.2021.32.e19. Epub 2020 Dec 2. J Gynecol Oncol. 2021. PMID: 33300314 Free PMC article. No abstract available.

References

    1. Ehmann ST, Zivanovic O, Chi D. Why was GOG-0213 a negative trial? J Gynecol Oncol. 2020;32:e19 - PMC - PubMed
    1. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–274. - PubMed
    1. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381:1929–1939. - PMC - PubMed
    1. Du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. 2020;38:6000.
    1. Zang R, Zhu J, Shi T, Liu J, Tu D, Yin S, et al. A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2. J Clin Oncol. 2020;38:6001.